Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Pseudotyped Lentivirus technology enhances traditional lentiviral vectors by replacing conventional envelope proteins, enabling precise targeting of specific tissues and cell types while preserving the core advantages of lentiviruses: efficient gene delivery, stable integration, and low immunogenicity.
Creative Biogene provides comprehensive pseudotyped lentivirus system construction services, offering end-to-end solutions from envelope protein screening and design to virus packaging, purification, and functional validation, meeting diverse needs across basic research, drug development, and preclinical translational applications.
Figure 1. Production of lentiviral vectors pseudotyped with the SARS-CoV-2 Spike glycoprotein (Mekkaoui L, et al., 2021)
While traditional lentivirus systems (based on HIV-1) possess efficient gene delivery capabilities, their native envelope proteins (such as HIV's gp120/gp41) limit their infection spectrum and exhibit poor stability in serum. Pseudotyping technology employs molecular substitution to recombine the lentiviral core with envelope proteins from other viruses (such as VSV-G from vesicular stomatitis virus, RV-G from rabies virus, MV-H/F from measles virus, etc.), creating engineered viral particles with specific tissue tropism, enhanced stability, and improved transduction efficiency.
Leveraging third-generation split-plasmid packaging systems, pseudotyped lentiviruses retain the core advantages of traditional lentiviruses:
Creative Biogene offers a wide range of envelope proteins to meet the needs of diverse applications.
| Envelope Type | Primary Target Cells/Tissues | Characteristics and Advantages |
| VSV-G | Broad spectrum | High stability, standard control, high titer |
| RV-G (Rabies Virus Glycoprotein) | Neurons, neural stem cells | Retrograde axonal transport capability, commonly used for neural circuit tracing |
| MV-H/F (Measles Virus) | CD46+/SLAM+ cells, primarily lymphocytes | Enhanced transduction efficiency for immune cells |
| SARS-CoV-2 Spike | ACE2-positive cells | Applied in COVID-19 invasion mechanism research and antiviral drug screening |
| Ebola GP | Endothelial cells, hepatocytes | Efficient liver targeting with blood-brain barrier crossing capability |
| BaEV | Hematopoietic stem cells | High transduction efficiency for non-activated HSCs |
| RD114-TR | T cells, hematopoietic stem cells | High packaging efficiency, low cytotoxicity, suitable for clinical-grade production |
| Nipah F/G | Pluripotent stem cells, neuronal cells | Good specificity for iPSCs/ESCs and pluripotent stem cells |
| FuG-B/B2 | Neurons, glial cells | Enhanced retrograde transport capability, suitable for neural circuit functional tracing |
| Custom Envelope | Specified as needed | Supports sequence or plasmid-based custom construction, enabling chimeric or novel designs |
1. Precise Targeted Delivery
2. Flexible Customizability
3. Extensive Application Experience
1Requirement communication: Complete the requirement form or contact the account manager, describe research objectives and technical requirements in detail
2Solution design: The Technical expert team evaluates requirements, provides 2-3 feasible technical solutions, and quotations
3Project initiation: Confirm solution, sign confidentiality agreement, and technical service contract
4Development and production: The Professional team executes according to the process, regularly reports progress
5Quality control and delivery: Strict quality control, issue a complete report, arrange logistics
6Application support: Provide a detailed operation manual, remote technical guidance, and ensure successful application
If you have any questions or requirements regarding our pseudotyped lentivirus technology services, please feel free to contact us at any time. Our professional team will respond to your inquiry within 24-48 hours and provide customized solutions and quotations based on your specific requirements. First-time consultations receive free experimental design evaluation and technical advice to help ensure the success of your research project.
Q: How do I select the most suitable envelope protein for my research?
A: Envelope selection is primarily based on three factors:
1) Target cell type and its surface receptor expression profile,
2) Experimental system (in vitro culture/in vivo model), and
3) Specific application requirements (such as stability, transduction efficiency, specificity, etc.)
We recommend clients provide target cell information (such as cell type, species, culture conditions) and the experimental purpose. Our expert team will recommend 2-3 most suitable envelope protein options based on our internal database and the latest literature.
Q: What advantages do specific envelopes have compared to traditional VSV-G pseudotyped lentiviruses?
A: While VSV-G is widely used for its broad tropism and high stability, specific envelopes demonstrate clear advantages in the following situations:
For example, in neuroscience research, RV-G or FuG-B envelopes enable retrograde tracing of neural circuits; for hematopoietic stem cells, the BaEV envelope significantly improves transduction efficiency of non-activated HSCs.
Q: How is the transduction efficiency of pseudotyped lentiviruses measured?
A: We employ multiple methods to evaluate transduction efficiency comprehensively:
We have established correction factors based on the characteristics of different envelope proteins to ensure accurate assessment. Clients can also opt for preliminary experiments on target cells to obtain actual transduction efficiency data under specific conditions.
Copyright © Creative Biogene. All rights reserved.